Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 11/2015

01-10-2015 | Guidelines

EANM practice guidelines for lymphoscintigraphy and sentinel lymph node biopsy in melanoma

Authors: Christina Bluemel, Ken Herrmann, Francesco Giammarile, Omgo E. Nieweg, Julien Dubreuil, Alessandro Testori, Riccardo A. Audisio, Odysseas Zoras, Michael Lassmann, Annette H. Chakera, Roger Uren, Sotirios Chondrogiannis, Patrick M. Colletti, Domenico Rubello

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 11/2015

Login to get access

Abstract

Purpose

Sentinel lymph node biopsy is an essential staging tool in patients with clinically localized melanoma. The harvesting of a sentinel lymph node entails a sequence of procedures with participation of specialists in nuclear medicine, radiology, surgery and pathology. The aim of this document is to provide guidelines for nuclear medicine physicians performing lymphoscintigraphy for sentinel lymph node detection in patients with melanoma.

Methods

These practice guidelines were written and have been approved by the European Association of Nuclear Medicine (EANM) to promote high-quality lymphoscintigraphy. The final result has been discussed by distinguished experts from the EANM Oncology Committee, national nuclear medicine societies, the European Society of Surgical Oncology (ESSO) and the European Association for Research and Treatment of Cancer (EORTC) melanoma group. The document has been endorsed by the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

Conclusion

The present practice guidelines will help nuclear medicine practitioners play their essential role in providing high-quality lymphatic mapping for the care of melanoma patients.
Literature
1.
Lens MB, Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol. 2004;150:179–85.PubMedCrossRef
2.
3.
Russak JE, Rigel DS. Risk factors for the development of primary cutaneous melanoma. Dermatol Clin. 2012;30:363–8.PubMedCrossRef
4.
Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199–206.PubMedCentralPubMedCrossRef
5.
Morton DL, Wanek L, Nizze JA, Elashoff RM, Wong JH. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg. 1991;214:491–501.PubMedCentralPubMedCrossRef
6.
Snow H. Melanotic cancerous disease. Lancet. 1892;2:872–4.
7.
Lens MB, Dawes M, Goodacre T, Newton-Bishop JA. Elective lymph node dissection in patients with melanoma: systematic review and meta-analysis of randomized controlled trials. Arch Surg. 2002;137:458–61.PubMed
8.
Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392–9.PubMedCrossRef
9.
10.
Thompson JF, McCarthy WH, Bosch CM, O’Brien CJ, Quinn MJ, Paramaesvaran S, et al. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res. 1995;5:255–60.PubMedCrossRef
11.
Reynolds HM, Dunbar PR, Uren RF, Blackett SA, Thompson JF, Smith NP. Three-dimensional visualisation of lymphatic drainage patterns in patients with cutaneous melanoma. Lancet Oncol. 2007;8:806–12.PubMedCrossRef
12.
Thompson JF, Uren RF. Lymphatic mapping in management of patients with primary cutaneous melanoma. Lancet Oncol. 2005;6:877–85.PubMedCrossRef
13.
Hunt JA, Thompson JF, Uren RF, Howman-Giles R, Harman CR. Epitrochlear lymph nodes as a site of melanoma metastasis. Ann Surg Oncol. 1998;5:248–52.PubMedCrossRef
14.
Thompson JF, Hunt JA, Culjak G, Uren RF, Howman-Giles R, Harman CR. Popliteal lymph node metastasis from primary cutaneous melanoma. Eur J Surg Oncol. 2000;26:172–6.PubMedCrossRef
15.
Uren RF, Howman-Giles R, Thompson JF. Lymphatic drainage from the skin of the back to retroperitoneal and paravertebral lymph nodes in melanoma patients. Ann Surg Oncol. 1998;5:384–7.PubMedCrossRef
16.
Uren RF, Howman-Giles R, Thompson JF. Patterns of lymphatic drainage from the skin in patients with melanoma. J Nucl Med. 2003;44:570–82.PubMed
17.
Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Nieweg OE, Roses DF, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370:599–609.PubMedCentralPubMedCrossRef
18.
Valsecchi ME, Silbermins D, de Rosa N, Wong SL, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis. J Clin Oncol. 2011;29:1479–87.PubMedCrossRef
19.
Statius Muller MG, Hennipman FA, van Leeuwen PA, Pijpers R, Vuylsteke RJ, Meijer S. Unpredictability of lymphatic drainage patterns in melanoma patients. Eur J Nucl Med Mol Imaging. 2002;29:255–61.PubMedCrossRef
20.
Vidal-Sicart S, Pons F, Fuertes S, Vilalta A, Rull R, Puig S, et al. Is the identification of in-transit sentinel lymph nodes in malignant melanoma patients really necessary? Eur J Nucl Med Mol Imaging. 2004;31:945–9.PubMedCrossRef
21.
Carling T, Pan D, Ariyan S, Narayan D, Truini C. Diagnosis and treatment of interval sentinel lymph nodes in patients with cutaneous melanoma. Plast Reconstr Surg. 2007;119:907–13.PubMedCrossRef
22.
McMasters KM, Chao C, Wong SL, Wrightson WR, Ross MI, Reintgen DS, et al. Interval sentinel lymph nodes in melanoma. Arch Surg. 2002;137:543–9.PubMedCrossRef
23.
Uren RF, Howman-Giles R, Thompson JF, McCarthy WH, Quinn MJ, Roberts JM, et al. Interval nodes: the forgotten sentinel nodes in patients with melanoma. Arch Surg. 2000;135:1168–72.PubMedCrossRef
24.
Zager JS, Puleo CA, Sondak VK. What is the significance of the in transit or interval sentinel node in melanoma? Ann Surg Oncol. 2011;18:3232–4.PubMedCrossRef
25.
Zogakis TG, Essner R, Wang HJ, Turner RR, Takasumi YT, Gaffney RL, et al. Melanoma recurrence patterns after negative sentinel lymphadenectomy. Arch Surg. 2005;140:865–72.PubMedCrossRef
26.
Morton DL, Cochran AJ, Thompson JF, Elashoff R, Essner R, Glass EC, et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg. 2005;242:302–13.PubMedCentralPubMed
27.
Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng CH, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17:976–83.PubMed
28.
Ahmed M, Purushotham AD, Douek M. Novel techniques for sentinel lymph node biopsy in breast cancer: a systematic review. Lancet Oncol. 2014;15:e351–62.PubMedCrossRef
29.
Giammarile F, Bozkurt MF, Cibula D, Pahisa J, Oyen WJ, Paredes P, et al. The EANM clinical and technical guidelines for lymphoscintigraphy and sentinel node localization in gynaecological cancers. Eur J Nucl Med Mol Imaging. 2014;41:1463–77.PubMedCrossRef
30.
Mitteldorf C, Bertsch HP, Jung K, Thoms KM, Schon MP, Tronnier M, et al. Sentinel node biopsy improves prognostic stratification in patients with thin (pT1) melanomas and an additional risk factor. Ann Surg Oncol. 2014;21:2252–8.PubMedCrossRef
31.
Bartlett EK, Gimotty PA, Sinnamon AJ, Wachtel H, Roses RE, Schuchter L, et al. Clark level risk stratifies patients with mitogenic thin melanomas for sentinel lymph node biopsy. Ann Surg Oncol. 2014;21:643–9.PubMedCentralPubMedCrossRef
32.
Balch CM, Thompson JF, Gershenwald JE, Soong SJ, Ding S, McMasters KM, et al. Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients. Ann Surg Oncol. 2014;21:1075–81.PubMedCentralPubMedCrossRef
33.
Sondak VK, Taylor JM, Sabel MS, Wang Y, Lowe L, Grover AC, et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol. 2004;11:247–58.PubMedCrossRef
34.
Glass EC, Essner R, Morton DL. Kinetics of three lymphoscintigraphic agents in patients with cutaneous melanoma. J Nucl Med. 1998;39:1185–90.PubMed
35.
Dummer R, Hauschild A, Guggenheim M, Keilholz U, Pentheroudakis G. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii86–91.PubMedCrossRef
36.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Melanoma. Version 4.2014. Fort Washington, PA: National Comprehensive Cancer Network; 2014.
37.
Wong SL, Balch CM, Hurley P, Agarwala SS, Akhurst TJ, Cochran A, et al. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol. 2012;30:2912–8.PubMedCrossRef
38.
Australian Cancer Network Melanoma Guidelines Revision Working Party: Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand. Cancer Council Australia and Australian Cancer Network, Sydney and New Zealand Guidelines Group, Wellington. 2008.
39.
Gajdos C, Griffith KA, Wong SL, Johnson TM, Chang AE, Cimmino VM, et al. Is there a benefit to sentinel lymph node biopsy in patients with T4 melanoma? Cancer. 2009;115:5752–60.PubMedCrossRef
40.
Gershenwald JE, Soong SJ, Balch CM. 2010 TNM staging system for cutaneous melanoma…and beyond. Ann Surg Oncol. 2010;17:1475–7.PubMedCrossRef
41.
Main BG, Coyle MJ, Godden A, Godden DR. The metastatic potential of head and neck cutaneous malignant melanoma: is sentinel node biopsy useful? Br J Oral Maxillofac Surg. 2014;52:340–3.PubMedCrossRef
42.
Newlands C, Gurney B. Management of regional metastatic disease in head and neck cutaneous malignancy. 2. Cutaneous malignant melanoma. Br J Oral Maxillofac Surg. 2014;52:301–7.PubMedCrossRef
43.
de Rosa N, Lyman GH, Silbermins D, Valsecchi ME, Pruitt SK, Tyler DM, et al. Sentinel node biopsy for head and neck melanoma: a systematic review. Otolaryngol Head Neck Surg. 2011;145:375–82.PubMedCrossRef
44.
Ishihara T, Kaguchi A, Matsushita S, Shiraishi S, Tomiguchi S, Yamashita Y, et al. Management of sentinel lymph nodes in malignant skin tumors using dynamic lymphoscintigraphy and the single-photon-emission computed tomography/computed tomography combined system. Int J Clin Oncol. 2006;11:214–20.PubMedCrossRef
45.
Stoffels I, Boy C, Poppel T, Kuhn J, Klotgen K, Dissemond J, et al. Association between sentinel lymph node excision with or without preoperative SPECT/CT and metastatic node detection and disease-free survival in melanoma. JAMA. 2012;308:1007–14.PubMedCrossRef
46.
Wasif N, Gray RJ, Pockaj BA. Desmoplastic melanoma – the step-child in the melanoma family? J Surg Oncol. 2011;103:158–62.PubMedCrossRef
47.
Smith VA, Lentsch EJ. Sentinel node biopsy in head and neck desmoplastic melanoma: an analysis of 244 cases. Laryngoscope. 2012;122:116–20.PubMedCrossRef
48.
George E, McClain SE, Slingluff CL, Polissar NL, Patterson JW. Subclassification of desmoplastic melanoma: pure and mixed variants have significantly different capacities for lymph node metastasis. J Cutan Pathol. 2009;36:425–32.PubMedCrossRef
49.
Han D, Zager JS, Yu D, Zhao X, Walls B, Marzban SS, et al. Desmoplastic melanoma: is there a role for sentinel lymph node biopsy? Ann Surg Oncol. 2013;20:2345–51.PubMedCentralPubMedCrossRef
50.
Beasley GM, Speicher P, Sharma K, Seigler H, Salama A, Mosca P, et al. Efficacy of repeat sentinel lymph node biopsy in patients who develop recurrent melanoma. J Am Coll Surg. 2014;218:686–92.PubMedCrossRef
51.
Yao KA, Hsueh EC, Essner R, Foshag LJ, Wanek LA, Morton DL. Is sentinel lymph node mapping indicated for isolated local and in-transit recurrent melanoma? Ann Surg. 2003;238:743–7.PubMedCentralPubMedCrossRef
52.
Gipponi M, Solari N, Giovinazzo D, Queirolo P, Bertoglio S, Villa G, et al. The role of sentinel lymph node biopsy in patients with local recurrence or in-transit metastasis of melanoma. Anticancer Res. 2014;34:3197–203.PubMed
53.
Papes D, Altarac S, Arslani N, Rajkovic Z, Antabak A, Cacic M. Melanoma of the glans penis and urethra. Urology. 2014;83:6–11.PubMedCrossRef
54.
Trifiro G, Travaini LL, Sanvito F, Pacifici M, Mallia A, Ferrari ME, et al. Sentinel node detection by lymphoscintigraphy and sentinel lymph node biopsy in vulvar melanoma. Eur J Nucl Med Mol Imaging. 2010;37:736–41.PubMedCrossRef
55.
Starek I, Koranda P, Benes P. Sentinel lymph node biopsy: a new perspective in head and neck mucosal melanoma? Melanoma Res. 2006;16:423–7.PubMedCrossRef
56.
Gourin CG, Conger BT, Porubsky ES, Sheils WC, Bilodeau PA, Coleman TA. The effect of occult nodal metastases on survival and regional control in patients with head and neck squamous cell carcinoma. Laryngoscope. 2008;118:1191–4.PubMedCrossRef
57.
Ahmed MM, Moore BA, Schmalbach CE. Utility of head and neck cutaneous squamous cell carcinoma sentinel node biopsy: a systematic review. Otolaryngol Head Neck Surg. 2014;150:180–7.PubMedCrossRef
58.
Thompson JF, Hruby G. The role of sentinel lymph node biopsy in patients with Merkel cell carcinoma: uncertainty prevails. Ann Surg Oncol. 2014;21:1517–9.PubMedCrossRef
59.
Gannon CJ, Rousseau Jr DL, Ross MI, Johnson MM, Lee JE, Mansfield PF, et al. Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma. Cancer. 2006;107:2647–52.PubMedCrossRef
60.
Evans HL, Krag DN, Teates CD, Patterson JW, Meijer S, Harlow SP, et al. Lymphoscintigraphy and sentinel node biopsy accurately stage melanoma in patients presenting after wide local excision. Ann Surg Oncol. 2003;10:416–25.PubMedCrossRef
61.
Andtbacka RH, Donaldson MR, Bowles TL, Bowen GM, Grossmann K, Khong H, et al. Sentinel lymph node biopsy for melanoma in pregnant women. Ann Surg Oncol. 2013;20:689–96.PubMedCrossRef
62.
Walton NK, Melachuri VK. Anaesthesia for non-obstetric surgery during pregnancy. Contin Educ Anaesth Crit Care Pain. 2006;6:83–5.CrossRef
63.
Howman-Giles R, Shaw HM, Scolyer RA, Murali R, Wilmott J, McCarthy SW, et al. Sentinel lymph node biopsy in pediatric and adolescent cutaneous melanoma patients. Ann Surg Oncol. 2010;17:138–43.PubMedCrossRef
64.
Ferrari A, Bisogno G, Cecchetto G, Santinami M, Maurichi A, Bono A, et al. Cutaneous melanoma in children and adolescents: the Italian rare tumors in pediatric age project experience. J Pediatr. 2014;164:376–82.PubMedCrossRef
65.
Roaten JB, Partrick DA, Pearlman N, Gonzalez RJ, Gonzalez R, McCarter MD. Sentinel lymph node biopsy for melanoma and other melanocytic tumors in adolescents. J Pediatr Surg. 2005;40:232–5.PubMedCrossRef
66.
Veenstra HJ, Wouters MW, Kroon BB, Olmos RA, Nieweg OE. Less false-negative sentinel node procedures in melanoma patients with experience and proper collaboration. J Surg Oncol. 2011;104:454–7.PubMedCrossRef
67.
Tanis PJ, Nieweg OE, Hart AA, Kroon BB. The illusion of the learning phase for lymphatic mapping. Ann Surg Oncol. 2002;9:142–7.PubMedCrossRef
68.
Ross GL, Shoaib T, Scott J, Soutar DS, Gray HW, MacKie R. The learning curve for sentinel node biopsy in malignant melanoma. Br J Plast Surg. 2002;55:298–301.PubMedCrossRef
69.
Morton DL, Thompson JF, Essner R, Elashoff R, Stern SL, Nieweg OE, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg. 1999;230:453–65.PubMedCentralPubMedCrossRef
70.
Vidal-Sicart S, Pons F, Puig S, Ortega M, Vilalta A, Martin F, et al. Identification of the sentinel lymph node in patients with malignant melanoma: what are the reasons for mistakes? Eur J Nucl Med Mol Imaging. 2003;30:362–6.PubMedCrossRef
71.
Karim RZ, Scolyer RA, Li W, Yee VS, McKinnon JG, Li LX, et al. False negative sentinel lymph node biopsies in melanoma may result from deficiencies in nuclear medicine, surgery, or pathology. Ann Surg. 2008;247:1003–10.PubMedCrossRef
72.
Chakera AH, Lock-Andersen J, Hesse U, Nurnberg BM, Juhl BR, Stokholm KH, et al. One-day or two-day procedure for sentinel node biopsy in melanoma? Eur J Nucl Med Mol Imaging. 2009;36:928–37.PubMedCrossRef
73.
Rossi CR, De Salvo GL, Trifiro G, Mocellin S, Landi G, Macripo G, et al. The impact of lymphoscintigraphy technique on the outcome of sentinel node biopsy in 1,313 patients with cutaneous melanoma: an Italian multicentric study (SOLISM-IMI). J Nucl Med. 2006;47:234–41.PubMed
74.
Vera DR, Wallace AM, Hoh CK. [(99m)Tc]MAG(3)-mannosyl-dextran: a receptor-binding radiopharmaceutical for sentinel node detection. Nucl Med Biol. 2001;28:493–8.PubMedCrossRef
75.
Sondak VK, King DW, Zager JS, Schneebaum S, Kim J, Leong SP, et al. Combined analysis of phase III trials evaluating [99mTc]tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically node-negative cutaneous melanoma. Ann Surg Oncol. 2013;20:680–8.PubMedCentralPubMedCrossRef
76.
77.
78.
Mariani G, Moresco L, Viale G, Villa G, Bagnasco M, Canavese G, et al. Radioguided sentinel lymph node biopsy in breast cancer surgery. J Nucl Med. 2001;42:1198–215.PubMed
79.
Gommans GM, van Dongen A, van der Schors TG, Gommans E, Visser JF, Clarijs WW, et al. Further optimisation of 99mTc-Nanocoll sentinel node localisation in carcinoma of the breast by improved labelling. Eur J Nucl Med. 2001;28:1450–5.PubMedCrossRef
80.
Elsinga P, Todde S, Penuelas I, Meyer G, Farstad B, Faivre-Chauvet A, et al. Guidance on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals. Eur J Nucl Med Mol Imaging. 2010;37:1049–62.PubMedCentralPubMedCrossRef
81.
Busemann Sokole E, Plachcinska A, Britten A, Lyra Georgosopoulou M, Tindale W, Klett R. Routine quality control recommendations for nuclear medicine instrumentation. Eur J Nucl Med Mol Imaging. 2010;37:662–71.PubMedCrossRef
82.
Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD, Siegel BA, et al. Procedure guideline for SPECT/CT imaging 1.0. J Nucl Med. 2006;47:1227–34.PubMed
83.
Nielsen KR, Chakera AH, Hesse B, Scolyer RA, Stretch JF, Thompson JF, et al. The diagnostic value of adding dynamic scintigraphy to standard delayed planar imaging for sentinel node identification in melanoma patients. Eur J Nucl Med Mol Imaging. 2011;38:1999–2004.PubMedCrossRef
84.
Thompson JF, Uren RF, Shaw HM, McCarthy WH, Quinn MJ, O’Brien CJ, et al. Location of sentinel lymph nodes in patients with cutaneous melanoma: new insights into lymphatic anatomy. J Am Coll Surg. 1999;189:195–204.PubMedCrossRef
85.
Matter M, Nicod Lalonde M, Allaoua M, Boubaker A, Lienard D, Gugerli O, et al. The role of interval nodes in sentinel lymph node mapping and dissection for melanoma patients. J Nucl Med. 2007;48:1607–13.PubMedCrossRef
86.
Zender C, Guo T, Weng C, Faulhaber P, Rezaee R. Utility of SPECT/CT for periparotid sentinel lymph node mapping in the surgical management of head and neck melanoma. Am J Otolaryngol. 2014;35:12–8.PubMedCrossRef
87.
Wagner T, Buscombe J, Gnanasegaran G, Navalkissoor S. SPECT/CT in sentinel node imaging. Nucl Med Commun. 2013;34:191–202.PubMedCrossRef
88.
Stoffels I, Muller M, Geisel MH, Leyh J, Poppel T, Schadendorf D, et al. Cost-effectiveness of preoperative SPECT/CT combined with lymphoscintigraphy vs. lymphoscintigraphy for sentinel lymph node excision in patients with cutaneous malignant melanoma. Eur J Nucl Med Mol Imaging. 2014;41:1723–31.PubMedCrossRef
89.
Keidar Z, Israel O, Krausz Y. SPECT/CT in tumor imaging: technical aspects and clinical applications. Semin Nucl Med. 2003;33:205–18.PubMedCrossRef
90.
Vermeeren L, Valdes Olmos RA, Klop WM, van der Ploeg IM, Nieweg OE, Balm AJ, et al. SPECT/CT for sentinel lymph node mapping in head and neck melanoma. Head Neck. 2011;33:1–6.PubMedCrossRef
91.
Conway WC, Faries MB, Nicholl MB, Terando AM, Glass EC, Sim M, et al. Age-related lymphatic dysfunction in melanoma patients. Ann Surg Oncol. 2009;16:1548–52.PubMedCentralPubMedCrossRef
92.
Uren RF, Howman-Giles RB, Thompson JF. Demonstration of second-tier lymph nodes during preoperative lymphoscintigraphy for melanoma: incidence varies with primary tumor site. Ann Surg Oncol. 1998;5:517–21.PubMedCrossRef
93.
Estourgie SH, Nieweg OE, Valdes Olmos RA, Hoefnagel CA, Kroon BB. Review and evaluation of sentinel node procedures in 250 melanoma patients with a median follow-up of 6 years. Ann Surg Oncol. 2003;10:681–8.PubMedCrossRef
94.
Nieweg OE, Jansen L, Kroon BB. Technique of lymphatic mapping and sentinel node biopsy for melanoma. Eur J Surg Oncol. 1998;24:520–4.PubMedCrossRef
95.
Leong SP, Donegan E, Heffernon W, Dean S, Katz JA. Adverse reactions to isosulfan blue during selective sentinel lymph node dissection in melanoma. Ann Surg Oncol. 2000;7:361–6.PubMedCrossRef
96.
97.
Mihaljevic AL, Rieger A, Belloni B, Hein R, Okur A, Scheidhauer K, et al. Transferring innovative freehand SPECT to the operating room: first experiences with sentinel lymph node biopsy in malignant melanoma. Eur J Surg Oncol. 2014;40:42–8.PubMedCrossRef
98.
Wendler T, Herrmann K, Schnelzer A, Lasser T, Traub J, Kutter O, et al. First demonstration of 3-D lymphatic mapping in breast cancer using freehand SPECT. Eur J Nucl Med Mol Imaging. 2010;37:1452–61.PubMedCrossRef
99.
Bluemel C, Herrmann K, Muller-Richter U, Lapa C, Higuchi T, Wild V, et al. Freehand SPECT-guided sentinel lymph node biopsy in early oral squamous cell carcinoma. Head Neck. 2014;36:E112–6.PubMedCrossRef
100.
Vermeeren L, Valdes Olmos RA, Klop WM, Balm AJ, van den Brekel MW. A portable gamma-camera for intraoperative detection of sentinel nodes in the head and neck region. J Nucl Med. 2010;51:700–3.PubMedCrossRef
101.
Hellingman D, de Wit-van der Veen LJ, Klop WM, Olmos RA. Detecting near-the-injection-site sentinel nodes in head and neck melanomas with a high-resolution portable gamma camera. Clin Nucl Med. 2014;40:e11–6.CrossRef
102.
Vidal-Sicart S, Paredes P, Zanon G, Pahisa J, Martinez-Roman S, Caparros X, et al. Added value of intraoperative real-time imaging in searches for difficult-to-locate sentinel nodes. J Nucl Med. 2010;51:1219–25.PubMedCrossRef
103.
Tanis PJ, Boom RP, Koops HS, Faneyte IF, Peterse JL, Nieweg OE, et al. Frozen section investigation of the sentinel node in malignant melanoma and breast cancer. Ann Surg Oncol. 2001;8:222–6.PubMedCrossRef
104.
Blessing K, Sanders DS, Grant JJ. Comparison of immunohistochemical staining of the novel antibody melan-A with S100 protein and HMB-45 in malignant melanoma and melanoma variants. Histopathology. 1998;32:139–46.PubMedCrossRef
105.
Prieto VG. Sentinel lymph nodes in cutaneous melanoma: handling, examination, and clinical repercussion. Arch Pathol Lab Med. 2010;134:1764–9.PubMed
106.
Cook MG, Green MA, Anderson B, Eggermont AM, Ruiter DJ, Spatz A, et al. The development of optimal pathological assessment of sentinel lymph nodes for melanoma. J Pathol. 2003;200:314–9.PubMedCrossRef
107.
van Akkooi AC, Spatz A, Eggermont AM, Mihm M, Cook MG. Expert opinion in melanoma: the sentinel node; EORTC Melanoma Group recommendations on practical methodology of the measurement of the microanatomic location of metastases and metastatic tumour burden. Eur J Cancer. 2009;45:2736–42.PubMedCrossRef
108.
van Akkooi AC, Nowecki ZI, Voit C, Schafer-Hesterberg G, Michej W, de Wilt JH, et al. Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes. Ann Surg. 2008;248:949–55.PubMedCrossRef
109.
Pasquali S, Mocellin S, Mozzillo N, Maurichi A, Quaglino P, Borgognoni L, et al. Nonsentinel lymph node status in patients with cutaneous melanoma: results from a multi-institution prognostic study. J Clin Oncol. 2014;32:935–41.PubMedCrossRef
110.
Govindarajan A, Ghazarian DM, McCready DR, Leong WL. Histological features of melanoma sentinel lymph node metastases associated with status of the completion lymphadenectomy and rate of subsequent relapse. Ann Surg Oncol. 2007;14:906–12.PubMedCrossRef
111.
Vuylsteke RJ, Borgstein PJ, van Leeuwen PA, Gietema HA, Molenkamp BG, Statius Muller MG, et al. Sentinel lymph node tumor load: an independent predictor of additional lymph node involvement and survival in melanoma. Ann Surg Oncol. 2005;12:440–8.PubMedCrossRef
112.
Gershenwald JE, Andtbacka RH, Prieto VG, Johnson MM, Diwan AH, Lee JE, et al. Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. J Clin Oncol. 2008;26:4296–303.PubMedCentralPubMedCrossRef
113.
114.
Freesmeyer M, Zanow J, Ludewig S, Drescher R. Multimodal imaging of aortoiliac occlusive disease with three-dimensional postprocessing of PET angiography and CT. Clin Imaging. 2014;38:877–9.PubMedCrossRef
115.
Chakera AH, Hesse B, Burak Z, Ballinger JR, Britten A, Caraco C, et al. EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. Eur J Nucl Med Mol Imaging. 2009;36:1713–42.PubMedCrossRef
116.
Waddington WA, Keshtgar MR, Taylor I, Lakhani SR, Short MD, Ell PJ. Radiation safety of the sentinel lymph node technique in breast cancer. Eur J Nucl Med. 2000;27:377–91.PubMedCrossRef
117.
ICRP publication 103: the 2007 Recommendations of the International Commission on Radiological Protection. Ann ICRP. 2007;37(2-4):1–332.
118.
Bronskill MJ. Radiation dose estimates for interstitial radiocolloid lymphoscintigraphy. Semin Nucl Med. 1983;13:20–5.PubMedCrossRef
119.
Castronovo Jr FP, McKusick KA, Strauss HW. Dosimetric consequences of radiopharmaceutical infiltrations. Invest Radiol. 1994;29:59–64.PubMedCrossRef
120.
Alazraki N, Glass EC, Castronovo F, Olmos RA, Podoloff D. Procedure guideline for lymphoscintigraphy and the use of intraoperative gamma probe for sentinel lymph node localization in melanoma of intermediate thickness 1.0. J Nucl Med. 2002;43:1414–8.PubMed
121.
Law M, Ma WH, Leung R, Li S, Wong KK, Ho WY, et al. Evaluation of patient effective dose from sentinel lymph node lymphoscintigraphy in breast cancer: a phantom study with SPECT/CT and ICRP-103 recommendations. Eur J Radiol. 2012;81:e717–20.PubMedCrossRef
122.
ICRP Publication 84: pregnancy and medical radiation. Ann ICRP. 2000;30(1):1–43.
123.
ICRP Publication 106: radiation dose to patients from radiopharmaceuticals: a third amendment to ICRP publication 53. Ann ICRP. 2008;38(1-2):1–197.
124.
Patel SJ, Reede DL, Katz DS, Subramaniam R, Amorosa JK. Imaging the pregnant patient for nonobstetric conditions: algorithms and radiation dose considerations. Radiographics. 2007;27:1705–22.PubMedCrossRef
125.
Lloyd MS, Topping A, Allan R, Powell B. Contraindications to sentinel lymph node biopsy in cutaneous malignant melanoma. Br J Plast Surg. 2004;57:725–7.PubMedCrossRef
126.
Gentilini O, Cremonesi M, Trifiro G, Ferrari M, Baio SM, Caracciolo M, et al. Safety of sentinel node biopsy in pregnant patients with breast cancer. Ann Oncol. 2004;15:1348–51.PubMedCrossRef
127.
128.
ICRP Publication 60: 1990 recommendations of the International Commission on Radiological Protection. Ann ICRP. 1991;21(1-3):1–201.
129.
European Commission: Off Eur J Commun No.L 159 J2. Council Directive 96/29/Euratom. 2006.
130.
European Commission: Off Eur J Commun No.L 159 J9. Council Directive 97/43/ Euratom. 2007.
131.
Michel R, Hofer C. Radiation safety precautions for sentinel lymph node procedures. Health Phys. 2004;86:S35–7.PubMedCrossRef
132.
Nejc D, Wrzesien M, Piekarski J, Olszewski J, Pluta P, Kusmierek J, et al. Sentinel node biopsy in skin melanoma patients – measurements of absorbed doses of radiation to the hands of medical staff. J Surg Oncol. 2006;93:355–61.PubMedCrossRef
133.
Sera T, Mohos G, Papos M, Osvay M, Varga J, Lazar M, et al. Sentinel node detection in malignant melanoma patients: radiation safety considerations. Dermatol Surg. 2003;29:141–5.PubMed
134.
Stratmann SL, McCarty TM, Kuhn JA. Radiation safety with breast sentinel node biopsy. Am J Surg. 1999;178:454–7.PubMedCrossRef
135.
Klausen TL, Chakera AH, Friis E, Rank F, Hesse B, Holm S. Radiation doses to staff involved in sentinel node operations for breast cancer. Clin Physiol Funct Imaging. 2005;25:196–202.PubMedCrossRef
136.
Schauer AJ, Becker W, Reiser M, Possinger K. The sentinel lymph node concept. Berlin: Springer; 2005. p. 5–9
137.
Strzelczyk I, Finlayson C. Sentinel node biopsy: ALARA and other considerations. Health Phys. 2004;86:31–4.CrossRef
138.
Glass EC, Basinski JE, Krasne DL, Giuliano AE. Radiation safety considerations for sentinel node techniques. Ann Surg Oncol. 1999;6:10–1.PubMedCrossRef
139.
IAEA. Nuclear medicine resources manual. Vienna: International Anatomic Energy Agency; 2006. p. 509–21.
140.
Nugent N, Hill AD, Casey M, Kelly L, Dijkstra B, Collins CD, et al. Safety guidelines for radiolocalised sentinel node resection. Ir J Med Sci. 2001;170:236–8.PubMedCrossRef
141.
Leong SP, Kim J, Ross M, Faries M, Scoggins CR, Metz WL, et al. A phase 2 study of (99m)Tc-tilmanocept in the detection of sentinel lymph nodes in melanoma and breast cancer. Ann Surg Oncol. 2011;18:961–9.PubMedCentralPubMedCrossRef
142.
Thill M, Kurylcio A, Welter R, van Haasteren V, Grosse B, Berclaz G, et al. The Central-European SentiMag study: sentinel lymph node biopsy with superparamagnetic iron oxide (SPIO) vs. radioisotope. Breast. 2014;23:175–9.PubMedCrossRef
143.
Verbeek FP, Troyan SL, Mieog JS, Liefers GJ, Moffitt LA, Rosenberg M, et al. Near-infrared fluorescence sentinel lymph node mapping in breast cancer: a multicenter experience. Breast Cancer Res Treat. 2014;143:333–42.PubMedCentralPubMedCrossRef
144.
Frontado LM, Brouwer OR, van den Berg NS, Matheron HM, Vidal-Sicart S, van Leeuwen FW, et al. Added value of the hybrid tracer indocyanine green-99mTc-nanocolloid for sentinel node biopsy in a series of patients with different lymphatic drainage patterns. Rev Esp Med Nucl Imagen Mol. 2013;32:227–33.PubMed
145.
van der Vorst JR, Schaafsma BE, Verbeek FP, Swijnenburg RJ, Hutteman M, Liefers GJ, et al. Dose optimization for near-infrared fluorescence sentinel lymph node mapping in patients with melanoma. Br J Dermatol. 2013;168:93–8.PubMedCentralPubMedCrossRef
146.
Nakagawa T, Minamiya Y, Katayose Y, Saito H, Taguchi K, Imano H, et al. A novel method for sentinel lymph node mapping using magnetite in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2003;126:563–7.PubMedCrossRef
147.
Olcott P, Pratx G, Johnson D, Mittra E, Niederkohr R, Levin CS. Clinical evaluation of a novel intraoperative handheld gamma camera for sentinel lymph node biopsy. Phys Med. 2014;30:340–5.PubMedCrossRef
148.
Stoffels I, Poeppel T, Boy C, Mueller S, Wichmann F, Dissemond J, et al. Radio-guided surgery: advantages of a new portable gamma-camera (Sentinella) for intraoperative real time imaging and detection of sentinel lymph nodes in cutaneous malignancies. J Eur Acad Dermatol Venereol. 2012;26:308–13.PubMedCrossRef
149.
Wendler T, Hartl A, Lasser T, Traub J, Daghighian F, Ziegler SI, et al. Towards intra-operative 3D nuclear imaging: reconstruction of 3D radioactive distributions using tracked gamma probes. Med Image Comput Comput Assist Interv. 2007;10:909–17.PubMed
Metadata
Title
EANM practice guidelines for lymphoscintigraphy and sentinel lymph node biopsy in melanoma
Authors
Christina Bluemel
Ken Herrmann
Francesco Giammarile
Omgo E. Nieweg
Julien Dubreuil
Alessandro Testori
Riccardo A. Audisio
Odysseas Zoras
Michael Lassmann
Annette H. Chakera
Roger Uren
Sotirios Chondrogiannis
Patrick M. Colletti
Domenico Rubello
Publication date
01-10-2015
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 11/2015
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-015-3135-1

Other articles of this Issue 11/2015

European Journal of Nuclear Medicine and Molecular Imaging 11/2015 Go to the issue

Original Article

Positron emission tomography of tumour [18F]fluoroestradiol uptake in patients with acquired hormone-resistant metastatic breast cancer prior to oestradiol therapy

Original Article

iROLL: does 3-D radioguided occult lesion localization improve surgical management in early-stage breast cancer?

Original Article

Do clinical, histological or immunohistochemical primary tumour characteristics translate into different 18F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer?

Original Article

Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment?

Original Article

Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype

Original Article

Diagnostic accuracy of 18F-FDG PET/CT compared with that of contrast-enhanced MRI of the breast at 3 T